VTVT (vTv Therapeutics) FFO


VTVT vTv Therapeutics Inc VTVT
35 GF Score
Price $34.49
GF Value $7,827.31
Valuation Significantly Undervalued
View Full Analysis

What is vTv Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

VTVT
35GF Score
vTv Therapeutics Inc VTVT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is vTv Therapeutics (VTVT) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of $34.49 is trading 99.6% below its estimated GF Value™ of $7,827.31. GuruFocus considers vTv Therapeutics to be Significantly Undervalued.

Key valuation signals for VTVT:

  • FFO:
  • GF Value™: $7,827.31 vs. price of $34.49 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the VTVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for VTVT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.49
Price
$7,827.31
GF Value